Sana Bio soars in stock market debut, raising $588M for cell & gene therapies February 5, 2021 Auto Bot BioPharma, biopharma nl, cancer, cell therapy, gene therapy, IPO, Seattle 0 Sana Biotechnology is turning new science into novel medicines intended to overcome limitations of current cell therapies. After going from stealth to IPO in two years, it’s now planning to bring multiple programs into clinical testing in 2022.